MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Background Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those in the general population. Previous evidence about the effects of lowering cholesterol in people with diabetes has been limited, and most diabetic patients do not currently receive cholesterol-lowering therapy despite their increased risk. Methods 5963 UK adults (aged 40-80 years) known to have diabetes, and an additional 14573 with occlusive arterial disease (but no diagnosed diabetes), were randomly allocated to receive 40 mg simvastatin daily or matching placebo. Prespecified analyses in these prior disease subcategories, and other relevant subcategories, were of first major coronary event (ie, non-fatal myocardial infarction or coronary death) and of first major vascular event (ie, major coronary event, stroke or revascularisation). Analyses were also conducted of subsequent vascular events during the scheduled treatment period. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, intention to treat), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period. Findings Both among the participants who presented with diabetes and among those who did not, there were highly significant reductions of about a quarter in the first event rate for major coronary events, for strokes, and for revasculari…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a wealth of literature demonstrating that statin therapy reduces incident cardiovascular events.70,71”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [70]
In the citing paper
“In the Heart Protection Study (lower age limit 40 years), the subgroup of $600 people with type 1 diabetes had a reduction in risk proportionately similar, although not statistically significant, to that in people with type 2 diabetes (102).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [102]
In the citing paper
“Subgroup analyses of people with diabetes in larger trials (101-105) and trials in people with diabetes (106,107) showed significant primary and secondary prevention of ASCVD events and CHD death in people with diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [102]
In the citing paper
“Subgroup analyses of people with diabetes in larger trials (94–98) and trials in people with diabetes (99,100) showed significant primary and secondary prevention of ASCVD events and coronary heart disease (CHD) death in people with diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [95]
In the citing paper
“In the Heart Protection Study (lower age limit 40 years), the subgroup of ∼600 people with type 1 diabetes had a reduction in risk proportionately similar, although not statistically significant, to that in people with type 2 diabetes (95).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [95]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Self-citationTurner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study
Garcia, M. J., McNamara, P. M., Gordon, T., & Kannell, W. B. (1974) · Diabetes · doi:10.2337/diab.23.2.105 · Cited by 1,608
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Nowy rok, stare problemy, ale i nowe możliwości
Czupryniak, L., & Diabetologicznego, P. P. T. (2014) · Via Medica Journals · Cited by 1,192
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986
(1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 970
Diabetes and atherosclerosis: An epidemiologic view
Pyörälä, K., Laakso, M., & Uusitupa, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 919
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D., Blackburn, H., Higgins, M., Reed, D., Iso, H., McMillan, G., Neaton, J., Nelson, J., Potter, J., & Rifkind, B. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus
Panzram, G. (1987) · Diabetologia · doi:10.1007/bf00274216 · Cited by 541
Chen, Z., Peto, R., Collins, R., MacMahon, S., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Self-citationWilson, K., Gibson, N., Willan, A., & Cook, D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.7.939 · Cited by 415
Standards of medical care for patients with diabetes mellitus
(1989) · The Journal of the American Osteopathic Association · doi:10.1515/jom-1989-890715 · Cited by 362
Acks, M. S., Arc, M., Feffer, A. P., Emuel, L., Oyé, A. M., Ouleau, J. E. L. R., Utherford, J. O. D. R., Ole, T. H. G. C., Rown, L. I. B., Arnica, J. W. A. W., et al. (1996) · Cited by 321
Management of Dyslipidemia in Adults With Diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s83 · Cited by 203
U.K. Prospective Diabetes Study Group (1997) · Diabetes Care · doi:10.2337/diacare.20.11.1683 · Cited by 129
Diet, Life-Style and Mortality in China
Donnan, S. (1992) · Journal of Epidemiology and Community Health · doi:10.1136/jech.46.4.462-b · Cited by 89
Variation in Diabetes Care Among States
Arday, D. R., Fleming, B. B., Keller, D. K., Pendergrass, P. W., Vaughn, R. J., Turpin, J. M., & Nicewander, D. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2230 · Cited by 84
Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort
Szatrowski, T. P., Peterson, A. V., Shimizu, Y., Prentice, R. L., Mason, M. W., Fukunaga, Y., & Kato, H. (1984) · Journal of Chronic Diseases · doi:10.1016/0021-9681(84)90007-9 · Cited by 62
ARMITAGE, J., & COLLINS, R. (2000) · Heart · doi:10.1136/heart.84.4.357 · Cited by 41
Self-citationPrior, M. J., Prout, T., Miller, D., Ewart, R., & Kumar, D. (1993) · Annals of Epidemiology · doi:10.1016/1047-2797(93)90004-n · Cited by 31
Quantitative Measurement of HbAlcby an Immunoturbidimetric Assay Compared to a Standard HPLC Method
Hamwi, A., Schweiger, C. R., Veitl, M., & Schmid, R. W. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.1.89 · Cited by 28
Yeo, W. W., & Yeo, W. W. (2002) · Heart · doi:10.1136/heart.87.5.423 · Cited by 8
Cited by
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Metadata
- Authors
- Collins, R., Armitage, J., Parish, S., Sleigh, P., & Peto, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2003-06
- Volume
- 361
- Issue
- 9374
- Pages
- 2005-2016
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1502524639
- Semantic Scholar
- ad50ed2cfdceacebfedbf9e0a0ad00ba26baf91e
- Cited by
- 2,876
- References
- 52
- Citations by year
- 2026: 18 · 2025: 16 · 2024: 45 · 2023: 55 · 2022: 39 · 2021: 36 · 2020: 66 · 2019: 81 · 2018: 72 · 2017: 63 · 2016: 94 · 2015: 110 · 2014: 157 · 2013: 156 · 2012: 147
- FWCI
- 244.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, diabetes mellitus, cholesterol-lowering therapy, LDL cholesterol, cardiovascular events, major coronary events, stroke, revascularization, arterial occlusive disease, cardiovascular risk reduction, statins, primary prevention, cardiovascular morbidity, myocardial infarction prevention
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alanine Transaminase, Anticholesteremic Agents, Cardiovascular Diseases, Creatine Kinase, Creatinine, Diabetes Mellitus, Female, Humans, Lipids, Male, Middle Aged, Myocardial Revascularization, Patient Compliance, Placebos, Prospective Studies, Risk Factors, Treatment Outcome, Simvastatin, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.